Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2016-05-24 Major Shareholding Noti…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2016
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding ('Holder: Adrianus van Herk') for BioInvent International Aktiebolag, specifically noting a 'Reason for major shareholding notification Sell' and providing exact figures for shares and voting rights percentages (9.34%). This structure—reporting changes in ownership thresholds by an individual or entity—is characteristic of a Major Shareholding Notification. This aligns directly with the definition for 'Major Shareholding Notification' (Code: MRQ). The document length is short (3793 chars), but the content is the notification itself, not an announcement of a report, so RPA/RNS is not the primary classification.
2016-05-24 English
Resolution at BioInvent’s Annual General Meeting 2016
AGM Information Classification · 99% confidence The document is explicitly titled 'Resolution at BioInvent's Annual General Meeting 2016' and details the outcomes of the meeting, including the election of board members, approval of financial statements for 2015, and resolutions regarding remuneration and incentive programs. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a press release summarizing the resolutions, not the formal voting results (DVA) or a general regulatory filing (RNS).
2016-05-12 English
Beslut på BioInvents årsstämma 2016
AGM Information Classification · 99% confidence The document is explicitly titled "Beslut på BioInvents årsstämma 2016" (Decisions at BioInvent's Annual General Meeting 2016) and details the resolutions passed, including board elections, approval of financial statements, remuneration decisions, and the introduction of an incentive program (stock options). These actions are the core components of an Annual General Meeting (AGM) outcome announcement. This directly corresponds to the AGM Information (AGM-R) category.
2016-05-12 Swedish
Major Shareholding Notification 2016
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding for 'Omega Fund IV, LP' in 'BioInvent International Aktiebolag', specifically reporting the 'Resulting distribution of total holdings' and the 'Percentage' of shares held (9.106%). This structure, focusing on changes in significant ownership thresholds, directly aligns with the definition of a Major Shareholding Notification. The code for this is MRQ.
2016-05-12 English
Major Shareholding Notification 2016
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage (7.18%) by a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension). It explicitly states the 'Reason for major shareholding notification' is 'New share issue' and provides the resulting share count and voting rights percentage. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2016-05-09 English
BioInvent’s Board Director Dharminder Chahal increases his shareholding in the company
Director's Dealing Classification · 98% confidence The document is a press release dated May 6, 2016, announcing that a Board Director, Dharminder Chahal, increased his shareholding in the company, now holding 5.02% of outstanding shares. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of 'Director's Dealing'. The appropriate code is DIRS.
2016-05-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.